Use of dipeptidyl peptidase iv effector for lowering blood glucose level in mammal
    1.
    发明专利
    Use of dipeptidyl peptidase iv effector for lowering blood glucose level in mammal 审中-公开
    用于降低血液中葡萄糖水平的DIPEPTIDYL PEPTIDASE IV效应

    公开(公告)号:JP2012092136A

    公开(公告)日:2012-05-17

    申请号:JP2011284809

    申请日:2011-12-27

    摘要: PROBLEM TO BE SOLVED: To provide a diabetes therapeutic composition.SOLUTION: This invention relates to a composition for inhibiting Dipeptidyl Peptidase (DPIV or CD 26) or DPIV-like enzyme activity, which can inhibit degradation of the endogenous, or exogenously administrated, insulinotropic peptides (incretins), Gastric Inhibitory Polypeptide/Glucose-dependent Insulinotropic Polypeptide 1-42 (GIP) and Glucagon-like Peptide-1 7-36 amide (GLP-1) (or analogs of these peptides). As a consequence of the enhanced stability of the endogenous, or exogenously administered, incretins or their analogs, their insulinotropic effects are enhanced, resulting in a potentate stimulation of insulin secretion from the pancreatic islets of Langerhans, and more rapid removal of glucose from the blood. In the composition, the inhibitor for inhibiting enzyme activity is alanyl pyrrolidide or aminoacyl thiazolidide.

    摘要翻译: 待解决的问题:提供糖尿病治疗组合物。 解决方案:本发明涉及抑制二肽基肽酶(DPIV或CD26)或DPIV样酶活性的组合物,其可以抑制内源或外源施用的促胰岛素肽(肠促胰岛素)的降解,胃抑制性多肽/ 葡萄糖依赖性胰岛素多肽1-42(GIP 1-42 )和胰高血糖素样肽-17-酰胺(GLP-1 )(或这些肽的类似物)。 由于内源或外源施用的肠溶素或其类似物的稳定性增强,其促胰岛素作用增强,导致胰岛素分泌从胰岛胰岛素的强烈刺激,并且从血液中更快速地除去葡萄糖 。 在该组合物中,抑制酶活性的抑制剂是吡咯烷丙酰丙氨酸或氨酰基噻唑烷。 版权所有(C)2012,JPO&INPIT